filmov
tv
COVID risk factors and implications

Показать описание
COVID-19 risk assessment tool
Work-based risk assessment
Model does not incorporate other external factors
High-risk household members
Those at higher risk of mental health issues
Pregnancy
There is currently insufficient data to make any meaningful assessment about the risk of COVID-19 to either the mother or the unborn child
Indeed the pandemic is not yet 9 months old
Until more information is available, we would recommend all people who are pregnant be regarded as high risk and offered the option to shield
Low Risk less than 3
Medium Risk 3-5
High Risk equal to or more than 6
Age
less than 50 1
more than 60 2
more than 70 4
more than 80 6
Sex at Birth
Female 0
Male 1
Ethnicity
Caucasian 0
Black African descent 2
Indian Asian descent 1
Filipino descent 1
Other (including Mixed race) 1
Diabetes
(Type 1 or Type 2) 1
(Type 1 or Type 2) 2
(Complicated diabetes = presence of microvascular complications or HbA1c≥64mmol/mol)
Obesity
BMI≥35kg/m2 1
Cardiovascular disease
Angina, previous MI, stroke
or cardiac intervention 1
Heart failure 2
Pulmonary disease
Asthma 1
Non-Asthma chronic pulmonary 2
Either above requiring oral corticosteroids in previous year 1
Malignant neoplasm
Active malignancy 3
Malignancy in remission 1
Rheumatological conditions
Active treated conditions 2
Immunosuppressant therapy
Any indication 2
More on comorbidities
European CDC (weeks 42, ending 18th October)
Sustained increase in cases over 2 weeks in 28 countries
At least 60 per 100 000
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK
Sustained increase over 2 weeks in 16 countries in over 65s
At least 60 per 100 000
Austria, Czechia, Denmark, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia, Spain and Sweden
Weekly test positivity, at least 3% or had increased against the previous week, 19 countries
Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Iceland, Ireland, Italy, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden
Vaccine, early months of next year, Matt Hancock
Oxford, AstraZeneca, AZD1222
30 million doses under UK manufacture
Roll-out first half of 2021
Some people vaccinated 2020
Immune response similar across all age groups
Strong immune response in elderly
Encouraging to see immunogenicity responses were similar between older and younger adults (AZ)
Lower levels of side-effects in older adults
Elderly usually have a reduced immune response (e.g. influenza vaccine)
Antibodies and T-cells
Brazil, India, South Africa, UK, US
Medicines and Healthcare products Regulatory Agency
Food and Drug Administration
Work-based risk assessment
Model does not incorporate other external factors
High-risk household members
Those at higher risk of mental health issues
Pregnancy
There is currently insufficient data to make any meaningful assessment about the risk of COVID-19 to either the mother or the unborn child
Indeed the pandemic is not yet 9 months old
Until more information is available, we would recommend all people who are pregnant be regarded as high risk and offered the option to shield
Low Risk less than 3
Medium Risk 3-5
High Risk equal to or more than 6
Age
less than 50 1
more than 60 2
more than 70 4
more than 80 6
Sex at Birth
Female 0
Male 1
Ethnicity
Caucasian 0
Black African descent 2
Indian Asian descent 1
Filipino descent 1
Other (including Mixed race) 1
Diabetes
(Type 1 or Type 2) 1
(Type 1 or Type 2) 2
(Complicated diabetes = presence of microvascular complications or HbA1c≥64mmol/mol)
Obesity
BMI≥35kg/m2 1
Cardiovascular disease
Angina, previous MI, stroke
or cardiac intervention 1
Heart failure 2
Pulmonary disease
Asthma 1
Non-Asthma chronic pulmonary 2
Either above requiring oral corticosteroids in previous year 1
Malignant neoplasm
Active malignancy 3
Malignancy in remission 1
Rheumatological conditions
Active treated conditions 2
Immunosuppressant therapy
Any indication 2
More on comorbidities
European CDC (weeks 42, ending 18th October)
Sustained increase in cases over 2 weeks in 28 countries
At least 60 per 100 000
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK
Sustained increase over 2 weeks in 16 countries in over 65s
At least 60 per 100 000
Austria, Czechia, Denmark, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia, Spain and Sweden
Weekly test positivity, at least 3% or had increased against the previous week, 19 countries
Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Iceland, Ireland, Italy, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden
Vaccine, early months of next year, Matt Hancock
Oxford, AstraZeneca, AZD1222
30 million doses under UK manufacture
Roll-out first half of 2021
Some people vaccinated 2020
Immune response similar across all age groups
Strong immune response in elderly
Encouraging to see immunogenicity responses were similar between older and younger adults (AZ)
Lower levels of side-effects in older adults
Elderly usually have a reduced immune response (e.g. influenza vaccine)
Antibodies and T-cells
Brazil, India, South Africa, UK, US
Medicines and Healthcare products Regulatory Agency
Food and Drug Administration
Комментарии